Press "Enter" to skip to content

Norway biotech Ultimovacs plans IPO to develop cancer drug

Ultimovacs hopes to first get the go-ahead to expand a U.S. trial launched earlier this year to test whether its UV1 vaccine candidate can combat malignant melanoma in combination with Merck & Co’s top-selling cancer treatment Keytruda.

Original source: https://health.economictimes.indiatimes.com/news/pharma/norway-biotech-ultimovacs-plans-ipo-to-develop-cancer-drug/66919103?utm_source=RSS&utm_medium=ETRSS

Also Read:   Ipca Labs signs pact with Medicines for Malaria Venture